Eupraxia Pharmaceuticals Inc.

NASDAQ:EPRX

Biotechnology

Healthcare
$6.21 +1.11%

+$0.07 today

Market cap
$417.57M
Beta
1.48
P/E (TTM)
-8.5
EPS (TTM)
-$0.74
52W Low $4.19High $9.32

Volume 1.21M

Average 0.22M

EPRX Gross Profit

Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.

Eupraxia Pharmaceuticals Inc.NASDAQ: EPRX

Gross Profit · Q1 FY2026 · quarter ended Mar 2026

Gross profit turns negative

Q1 FY2026 gross profit was -$88.9K, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$151.18K.

Context

  • Gross profit increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly gross profit holds near -$88.9K or moves back toward the trailing-twelve-month quarterly average of -$37.8K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$88.9K— QoQ
Last fiscal yearDec 2025
-$331.89K-103.0% YoY
LTMMar 2026
-$151.18K-13.6% YoY
Gross Profit past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-103.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Gross Profit history

Mixed currencies · from the income statement

Latest · FY2025
(331.89K) USD
Year-over-year change
-103.0%

Gross Profit vs competitors

How EPRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -13.6% is the 4th highest of 6, against a peer median of +2.7%.
EPRX Competitors
Gross Profit for EPRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 2026$32.49M USD+1115.8%+118.1%99.3%
MDWDMediWound Ltd.LTM Mar 2026$2.84M USD+2.7%-37.2%19.6%
IVAInventiva S.A.FY2025€1.51M EUR-83.6%-55.4%33.7%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$0 USD———
AARDAardvark Therapeutics, Inc. Common StockLTM Mar 2026$0 USD———
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026-$31.98K USD———
TARAProtara Therapeutics, Inc.LTM Mar 2026-$90K USD———
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026-$151.18K USD-13.6%——
NAUTNautilus Biotechnology, Inc.LTM Mar 2026-$6.32M USD+43.5%——
RNACCartesian Therapeutics, Inc.LTM Mar 2026-$11.02M USD-132.3%-70.5%621.0%
Peer median (excluding EPRX) —+2.7%-46.3%66.5%

Competitors are the stored peer set for EPRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · USD
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Revenue00000
Cost of Revenue112.38K00163.47K331.89K
Gross Profit(112.38K)00(163.47K)(331.89K)
Gross Margin—————
Research & Development7.59M13.63M15.33M16.07M29.51M
Selling, General & Admin6.97M3.99M5.63M10.92M17.1M
Operating Expenses14.65M17.62M20.97M26.99M53.33M
Depreciation & Amortization87.47K147.89K117.1K171.6K331.89K
EBITDA(17.22M)(17.86M)(20.78M)(24.95M)(53.33M)
EBITDA Margin—————
Operating Income(14.65M)(17.62M)(20.97M)(26.99M)(53.66M)
Operating Margin—————
Interest Income51.55K431.8K649.75K1.16M1.41M
Interest Expense1.02M982.86K881.05K603.17K0
Other Income / Expenses(3.68M)(1.37M)(814.93K)1.26M(212.94K)
Income Before Tax(18.33M)(18.99M)(21.78M)(25.73M)(53.87M)
Pre-Tax Margin—————
Income Tax Expense0027.42K1.8K26.65K
Net Income(18.03M)(18.49M)(21.25M)(25.49M)(53.86M)
Net Margin—————
EPS (Basic)(1.63)(0.96)(0.88)(0.76)(1.05)
EPS (Diluted)(1.63)(0.96)(0.88)(0.76)(1.05)
Weighted Avg Shares14.24M19.29M24.15M33.93M39.96M
Weighted Avg Shares (Diluted)14.24M19.29M24.15M33.93M39.96M

Eupraxia Pharmaceuticals Inc.

NASDAQ:EPRX

Intrinsic Alpha fair value

Locked

Current Price

$6.21

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.